Research Article
BibTex RIS Cite
Year 2020, Volume: 10 Issue: 3, 228 - 234, 29.09.2020

Abstract

Supporting Institution

Ağrı İbrahim Çeçen Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi

Project Number

ECZF.17.001

References

  • [1] Schomburg I, Chang A and Schomburg, D. BRENDA, enzyme data and metabolic information. Nucleic acids research 2002, 30 (1), 47–49.
  • [2] Sarioglu N, Bilen C, Sackes Z, Gencer N. The effects of bronchodilator drugs and antibiotics used for respiratory infection on human erythrocyte carbonic anhydrase I and II isozymes. Archives of physiology and biochemistry 2015, 121(2), 56-61.
  • [3] Li S, An L, Duan Q, Araneta MF, Johnson CS, Shen J. Determining the rate of carbonic anhydrase reaction in the human brain. Scientific reports 2018, 8(1), 2328.
  • [4] Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Review article. Journal of enzyme inhibition and medicinal chemistry 2004, 19(3), 199-229.
  • [5] Erzengin Z, Bilen C, Ergun A, Gencer N. Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors. Archives of physiology and biochemistry 2014, 120(1), 29-33. [6] Güleç Ö, Arslan M, Gencer N, Ergun A, Bilen C, Arslan O. Synthesis and carbonic anhydrase inhibitory properties of new spiroindoline-substituted sulphonamide compounds. Archives of physiology and biochemistry 2017, 123(5), 306-312. [7] Bayindir S, Temel Y, Ayna A, Ciftci M. The synthesis of N‐benzoylindoles as inhibitors of rat erythrocyte glucose‐6‐phosphate dehydrogenase and 6‐phosphogluconate dehydrogenase. Journal of biochemical and molecular toxicology 2018, 32(9), e22193.
  • [8] Ma L and Cheng Q. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochemical and biophysical research communications 2018, 498 (4), 912–917.
  • [9] Tandoğan B and Ulusu NN. 6-phosphogluconate dehydrogenase: molecular and kinetic properties. Turkish journal of biochemistry 2003, 28 (4), 268–273.
  • [10] Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T, ... Xie J. Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Molecular cell 2014, 55(4), 552-565.
  • [11] Zou Q, Chen YF, Zheng XQ, Ye SF, Xu BY, Liu YX, Zeng HH. Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression. Journal of Zhejiang University-SCIENCE B 2018, 19(9), 689-698. [12] Tuladhar A, Hondal RJ, Colon R, Hernandez EL, Rein KS. Effectors of thioredoxin reductase: Brevetoxins and manumycin-A. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2019, 217, 76-86.
  • [13] Lillig CH and Holmgren A. Thioredoxin and related molecules–from biology to health and disease. Antioxidants & redox signaling 2007, 9 (1), 25–47.
  • [14] Fernandes AP. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology 2009, 55 (3), 313–320.
  • [15] Wu R, Yao PA, Wang HL, Gao Y, Yu HL, Wang L, ... Gao JP. Effect of fermented Cordyceps sinensis on doxorubicin‑induced cardiotoxicity in rats. Molecular medicine reports 2018, 18(3), 3229-3241.
  • [16] Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochemical Journal 2002, 367(Pt 3), 729.
  • [17] Wen SH, Su SC, Liou BH, Lin CH, Lee KR. Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells. Cancer cell international 2018, 18(1), 128.
  • [18] Benzer F, Kandemir FM, Kucukler S, Comaklı S, Caglaya C. Chemoprotective effects of curcumin on doxorubicin-induced nephrotoxicity in wistar rats: by modulating inflammatory cytokines, apoptosis, oxidative stress and oxidative DNA damage. Archives of physiology and biochemistry 2018, 124(5), 448-457.
  • [19] Martin HL, Smith L and Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast cancer: targets and therapy 2014, 6, 1–13.
  • [20] Yu J, Wang C, Kong Q, Wu X, Lu JJ, Chen X. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine 2018, 40, 125-139.
  • [21] Ahmad A, Kaleem M, Ahmed Z, Shafiq H. Therapeutic potential of flavonoids and their mechanism of action against microbial and viral infections—A review. Food Research International 2015, 77, 221-235.
  • [22] Lee HS, Jung KH, Hong SW, Park IS, Lee C, Han HK, ... Hong SS. Morin protects acute liver damage by carbon tetrachloride (CCl 4) in rat. Archives of pharmacal research 2008, 31(9), 1160-1165.
  • [23] Al-Numair KS, Chandramohan G, Alsaif MA, Veeramani C, Newehy AE. Morin, a flavonoid, on lipid peroxidation and antioxidant status in experimental myocardial ischemic rats. African Journal of Traditional, Complementary and Alternative Medicines 2014, 11(3), 14-20.
  • [24] Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, Sultana S. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicology mechanisms and methods 2013, 23(5), 337-345.
  • [25] Verpoorte J, Mehta S and Edsall JT. Esterase activities of human carbonic anhydrases B and C. Journal of biological chemistry 1967, 242 (18), 4221–4229.
  • [26] Beutler E. Red cell metabolism. Manual of biochemical methods. Academic press, London; 1971.
  • [27] Holmgren A and Bjornstedt M [21] Thioredoxin and thioredoxin reductase. Methods in enzymology 1995, 252, 199–208.
  • [28] Bieg D, Sypniewski D, Nowak E, Bednarek I. Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Archives of gynecology and obstetrics 2018, 298(6), 1181-1194.
  • [29] Kandhare A, Mukherjee A, Bodhankar S. Anti-epileptic effect of morin against experimental pentylenetetrazol-induced seizures via modulating brain monoamines and oxidative stress. Asian pacific journal of tropical biomedicine 2018, 8 (7), 352-359.
  • [30] Thangarajan S, Vedagiri A, Somasundaram S, Sakthimanogaran R, Murugesan M. Neuroprotective effect of morin on lead acetate-induced apoptosis by preventing cytochrome c translocation via regulation of Bax/Bcl-2 ratio. Neurotoxicology and teratology 2018, 66, 35-45.
  • [31] Zhou Y, Cao ZQ, Wang HY, Cheng YN, Yu LG, Zhang XK, ... Guo XL. The anti‐inflammatory effects of Morin hydrate in atherosclerosis is associated with autophagy induction through cAMP signaling. Molecular nutrition & food research 2017, 61(9), 1600966.
  • [32] Choi JS, Burm JP. Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Archives of pharmacal research 2006, 29 (4), 333–338.
  • [33] MadanKumar P, NaveenKumar P, Devaraj H, NiranjaliDevaraj S. Morin, a dietary flavonoid, exhibits anti-fibrotic effect and induces apoptosis of activated hepatic stellate cells by suppressing canonical NF-κB signaling. Biochimie 2015, 110, 107-118.
  • [34] Razavi T, Kouhsari S and Abnous K. Morin exerts anti-diabetic effects in human HepG2 cells via down-regulation of miR-29a. Experimental and clinical endocrinology & diabetes 2018, 23 (5), 337-345.
  • [35] Yue M, Zeng N, Xia Y, Wei Z, Dai Y. Morin Exerts Anti‐Arthritic Effects by Attenuating Synovial Angiogenesis via Activation of Peroxisome Proliferator Activated Receptor‐γ. Molecular nutrition & food research 2018, 62(21), 1800202.
  • [36] Choi HJ and Choi J-S. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Archives of pharmacal research 2005, 28 (8), 970–976.
  • [37] Li B, Jin X, Meng H, Hu B, Zhang T, Yu J, ...Wang J. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget 2017, 8(29), 47849.
  • [38] Injac R and Strukelj B. Recent advances in protection against doxorubicin-induced toxicity. Technology in cancer research & treatment 2008, 7 (6), 497–516.
  • [39] Ahmed F, Urooj A, Karim AA. Protective effects of Ficus racemosa stem bark against doxorubucin-induced renal and testicular toxicity. Pharmacognosy magazine 2013, 9 (34), 130–134.
  • [40] Fouad AA and Yacoubi MT. Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity. Archives of pharmacal research 2011, 34 (5), 821–828.
  • [41] You J-S, Pan T-L and Lee Y-S. Protective effects of Danshen (Salvia Miltiorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats. Phytotherapy research 2007, 21 (12), 1146–1152.
  • [42] Minchin RF, Johnston MR, Schuller HM, Aiken MA, Boyd MR. Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer 1988, 61(7), 1320-1325.
  • [43] Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 2006, 218(2-3), 164-171.
  • [44] Henry RP. Multiple Roles of carbonic anhydrase in cellular transport and metabolism. Annual review of physiology 1996, 58 (1), 523–538.
  • [45] Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature reviews drug discovery 2008, 7 (2), 168–181.
  • [46] Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert opinion on therapeutic patents 2003, 13 (10), 1545–1550.
  • [47] Švastová E, Hulı́ková A, Rafajová M, Zat'ovičová M, Gibadulinová A, Casini A, Pastoreková S. Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH. FEBS letters 2004, 577(3), 439-445.
  • [48] Mogensen EG, Janbon G, Chaloupka J, Steegborn C, Fu MS, Moyrand F, ... Levin LR. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. Eukaryotic cell 2006, 5(1), 103-111.
  • [49] Sun M-K and Alkon DL. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends in pharmacological sciences 2002, 23 (2), 83–89.
  • [50] Ekinci D, Karagoz L, Ekinci D, Senturk M, Supuran CT. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. Journal of enzyme inhibition and medicinal chemistry 2013, 28(2), 283-288.
  • [51] Gocer H, Topal F, Topal M, Küçük M, Teke D, Gülçin İ, Supuran CT. Acetylcholinesterase and carbonic anhydrase isoenzymes I and II inhibition profiles of taxifolin. Journal of enzyme inhibition and medicinal chemistry 2016, 31(3), 441-447.
  • [52] Kuzu M, Özkaya A, Şahin Z, Dağ Ü, Comakli V, Demirdağ R. In Vivo Effects of Naringenin and Lead on Rat Erythrocyte Carbonic Anhydrase Enzyme. Turk J Pharm Sci 2017, 14(1), 9-12.
  • [53] Kuzu M and Ciftci M. Purification and characterization of NADPH-cytochrome P450 reductase from Lake Van fish liver microsomes and investigation of some chemical and metals’ effects on the enzyme activity. Turkish journal of chemistry 2015, 39 (1), 149-158.
  • [54] Katzenmeyer JB, Eddy CV and Arriaga EA. Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin. Analytical Chemistry 2010, 82 (19), 8113–8120.
  • [55] Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature reviews cancer 2011, 11(2), 85–95.
  • [56] Lin R, Elf S, Shan C, Kang HB, Ji Q. Zhou L,...Xie J. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1–AMPK signalling. Nature cell biology 2015, 17(11), 1484.
  • [57] Yang X, Peng X and Huang J. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clinical and translational oncology 2018, 20 (9), 1145–1152.
  • [58] Mitchell I and Deshpande N. Drug effects on certain enzymes of carbohydrate metabolism in MCF-7 cells in culture. Clinical oncology 1984, 10 (3), 253–260.
  • [59] Bindoli A, Rigobello MP, Scutari G, Gabbiani C, Casini A, Messori L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coordination Chemistry Reviews 2009, 253(11-12), 1692-1707.
  • [60] Arnér ESJ and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. European journal of biochemistry 2000, 267 (20), 6102-6109.
  • [61] Berggren M, Gallegos A, Gasdaska JR, Gasdaska P, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer research 1996, 16(6B), 3459-3466.
  • [62] Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, Moos PJ. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 2006, 27(12), 2538-2549.
  • [63] Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. Journal of Biological Chemistry 2006, 281(19), 13005-13008.
  • [64] Korać B and Buzadžić B. Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. Journal of dermatological science 2001, 25 (1), 45–52.

Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin

Year 2020, Volume: 10 Issue: 3, 228 - 234, 29.09.2020

Abstract

Objective:
Carbonic anhydrase (CA), 6-phosphogluconate dehydrogenase (6PGD) and
thioredoxin reductase (TrxR) enzymes are the essential biological molecules needed for metabolic processes in all living
cells. This study was designed to investigate the activities of CA, 6PGD and
TrxR enzymes in the brain, kidney, liver, heart and testis tissues of the rats
exposed to Dox and morin.



Methods:
Male Wistar albino rats were randomly divided into three groups as control,
morin and DOX, each of them containing 7 rats. At the end of the experimental
procedure, CA, 6PGD and TrxR enzyme activities in tissues of rats were
determined spectrophotometrically.



Results:
In our study, we observed that DOX activated CA enzyme in liver and kidney
tissues while inhibiting CA enzyme in the other tissues, activated 6PGD enzyme in the kidney, liver and heart
tissues, and inhibited the TrxR enzyme in all the tissues. In addition, morin
activated CA enzyme in the liver tissue while inhibiting CA enzyme in the
brain, heart and testis tissues. Morin activated 6PGD enzyme activity while it inhibited TrxR enzyme in all the tissues.



Conclusion:
The findings showed that doxorubicin and morin had similar properties in the
tissues as to their effect on enzyme activities.

Project Number

ECZF.17.001

References

  • [1] Schomburg I, Chang A and Schomburg, D. BRENDA, enzyme data and metabolic information. Nucleic acids research 2002, 30 (1), 47–49.
  • [2] Sarioglu N, Bilen C, Sackes Z, Gencer N. The effects of bronchodilator drugs and antibiotics used for respiratory infection on human erythrocyte carbonic anhydrase I and II isozymes. Archives of physiology and biochemistry 2015, 121(2), 56-61.
  • [3] Li S, An L, Duan Q, Araneta MF, Johnson CS, Shen J. Determining the rate of carbonic anhydrase reaction in the human brain. Scientific reports 2018, 8(1), 2328.
  • [4] Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Review article. Journal of enzyme inhibition and medicinal chemistry 2004, 19(3), 199-229.
  • [5] Erzengin Z, Bilen C, Ergun A, Gencer N. Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors. Archives of physiology and biochemistry 2014, 120(1), 29-33. [6] Güleç Ö, Arslan M, Gencer N, Ergun A, Bilen C, Arslan O. Synthesis and carbonic anhydrase inhibitory properties of new spiroindoline-substituted sulphonamide compounds. Archives of physiology and biochemistry 2017, 123(5), 306-312. [7] Bayindir S, Temel Y, Ayna A, Ciftci M. The synthesis of N‐benzoylindoles as inhibitors of rat erythrocyte glucose‐6‐phosphate dehydrogenase and 6‐phosphogluconate dehydrogenase. Journal of biochemical and molecular toxicology 2018, 32(9), e22193.
  • [8] Ma L and Cheng Q. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochemical and biophysical research communications 2018, 498 (4), 912–917.
  • [9] Tandoğan B and Ulusu NN. 6-phosphogluconate dehydrogenase: molecular and kinetic properties. Turkish journal of biochemistry 2003, 28 (4), 268–273.
  • [10] Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T, ... Xie J. Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Molecular cell 2014, 55(4), 552-565.
  • [11] Zou Q, Chen YF, Zheng XQ, Ye SF, Xu BY, Liu YX, Zeng HH. Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression. Journal of Zhejiang University-SCIENCE B 2018, 19(9), 689-698. [12] Tuladhar A, Hondal RJ, Colon R, Hernandez EL, Rein KS. Effectors of thioredoxin reductase: Brevetoxins and manumycin-A. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2019, 217, 76-86.
  • [13] Lillig CH and Holmgren A. Thioredoxin and related molecules–from biology to health and disease. Antioxidants & redox signaling 2007, 9 (1), 25–47.
  • [14] Fernandes AP. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology 2009, 55 (3), 313–320.
  • [15] Wu R, Yao PA, Wang HL, Gao Y, Yu HL, Wang L, ... Gao JP. Effect of fermented Cordyceps sinensis on doxorubicin‑induced cardiotoxicity in rats. Molecular medicine reports 2018, 18(3), 3229-3241.
  • [16] Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochemical Journal 2002, 367(Pt 3), 729.
  • [17] Wen SH, Su SC, Liou BH, Lin CH, Lee KR. Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells. Cancer cell international 2018, 18(1), 128.
  • [18] Benzer F, Kandemir FM, Kucukler S, Comaklı S, Caglaya C. Chemoprotective effects of curcumin on doxorubicin-induced nephrotoxicity in wistar rats: by modulating inflammatory cytokines, apoptosis, oxidative stress and oxidative DNA damage. Archives of physiology and biochemistry 2018, 124(5), 448-457.
  • [19] Martin HL, Smith L and Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast cancer: targets and therapy 2014, 6, 1–13.
  • [20] Yu J, Wang C, Kong Q, Wu X, Lu JJ, Chen X. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine 2018, 40, 125-139.
  • [21] Ahmad A, Kaleem M, Ahmed Z, Shafiq H. Therapeutic potential of flavonoids and their mechanism of action against microbial and viral infections—A review. Food Research International 2015, 77, 221-235.
  • [22] Lee HS, Jung KH, Hong SW, Park IS, Lee C, Han HK, ... Hong SS. Morin protects acute liver damage by carbon tetrachloride (CCl 4) in rat. Archives of pharmacal research 2008, 31(9), 1160-1165.
  • [23] Al-Numair KS, Chandramohan G, Alsaif MA, Veeramani C, Newehy AE. Morin, a flavonoid, on lipid peroxidation and antioxidant status in experimental myocardial ischemic rats. African Journal of Traditional, Complementary and Alternative Medicines 2014, 11(3), 14-20.
  • [24] Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, Sultana S. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicology mechanisms and methods 2013, 23(5), 337-345.
  • [25] Verpoorte J, Mehta S and Edsall JT. Esterase activities of human carbonic anhydrases B and C. Journal of biological chemistry 1967, 242 (18), 4221–4229.
  • [26] Beutler E. Red cell metabolism. Manual of biochemical methods. Academic press, London; 1971.
  • [27] Holmgren A and Bjornstedt M [21] Thioredoxin and thioredoxin reductase. Methods in enzymology 1995, 252, 199–208.
  • [28] Bieg D, Sypniewski D, Nowak E, Bednarek I. Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Archives of gynecology and obstetrics 2018, 298(6), 1181-1194.
  • [29] Kandhare A, Mukherjee A, Bodhankar S. Anti-epileptic effect of morin against experimental pentylenetetrazol-induced seizures via modulating brain monoamines and oxidative stress. Asian pacific journal of tropical biomedicine 2018, 8 (7), 352-359.
  • [30] Thangarajan S, Vedagiri A, Somasundaram S, Sakthimanogaran R, Murugesan M. Neuroprotective effect of morin on lead acetate-induced apoptosis by preventing cytochrome c translocation via regulation of Bax/Bcl-2 ratio. Neurotoxicology and teratology 2018, 66, 35-45.
  • [31] Zhou Y, Cao ZQ, Wang HY, Cheng YN, Yu LG, Zhang XK, ... Guo XL. The anti‐inflammatory effects of Morin hydrate in atherosclerosis is associated with autophagy induction through cAMP signaling. Molecular nutrition & food research 2017, 61(9), 1600966.
  • [32] Choi JS, Burm JP. Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Archives of pharmacal research 2006, 29 (4), 333–338.
  • [33] MadanKumar P, NaveenKumar P, Devaraj H, NiranjaliDevaraj S. Morin, a dietary flavonoid, exhibits anti-fibrotic effect and induces apoptosis of activated hepatic stellate cells by suppressing canonical NF-κB signaling. Biochimie 2015, 110, 107-118.
  • [34] Razavi T, Kouhsari S and Abnous K. Morin exerts anti-diabetic effects in human HepG2 cells via down-regulation of miR-29a. Experimental and clinical endocrinology & diabetes 2018, 23 (5), 337-345.
  • [35] Yue M, Zeng N, Xia Y, Wei Z, Dai Y. Morin Exerts Anti‐Arthritic Effects by Attenuating Synovial Angiogenesis via Activation of Peroxisome Proliferator Activated Receptor‐γ. Molecular nutrition & food research 2018, 62(21), 1800202.
  • [36] Choi HJ and Choi J-S. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Archives of pharmacal research 2005, 28 (8), 970–976.
  • [37] Li B, Jin X, Meng H, Hu B, Zhang T, Yu J, ...Wang J. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget 2017, 8(29), 47849.
  • [38] Injac R and Strukelj B. Recent advances in protection against doxorubicin-induced toxicity. Technology in cancer research & treatment 2008, 7 (6), 497–516.
  • [39] Ahmed F, Urooj A, Karim AA. Protective effects of Ficus racemosa stem bark against doxorubucin-induced renal and testicular toxicity. Pharmacognosy magazine 2013, 9 (34), 130–134.
  • [40] Fouad AA and Yacoubi MT. Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity. Archives of pharmacal research 2011, 34 (5), 821–828.
  • [41] You J-S, Pan T-L and Lee Y-S. Protective effects of Danshen (Salvia Miltiorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats. Phytotherapy research 2007, 21 (12), 1146–1152.
  • [42] Minchin RF, Johnston MR, Schuller HM, Aiken MA, Boyd MR. Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer 1988, 61(7), 1320-1325.
  • [43] Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 2006, 218(2-3), 164-171.
  • [44] Henry RP. Multiple Roles of carbonic anhydrase in cellular transport and metabolism. Annual review of physiology 1996, 58 (1), 523–538.
  • [45] Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature reviews drug discovery 2008, 7 (2), 168–181.
  • [46] Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert opinion on therapeutic patents 2003, 13 (10), 1545–1550.
  • [47] Švastová E, Hulı́ková A, Rafajová M, Zat'ovičová M, Gibadulinová A, Casini A, Pastoreková S. Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH. FEBS letters 2004, 577(3), 439-445.
  • [48] Mogensen EG, Janbon G, Chaloupka J, Steegborn C, Fu MS, Moyrand F, ... Levin LR. Cryptococcus neoformans senses CO2 through the carbonic anhydrase Can2 and the adenylyl cyclase Cac1. Eukaryotic cell 2006, 5(1), 103-111.
  • [49] Sun M-K and Alkon DL. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends in pharmacological sciences 2002, 23 (2), 83–89.
  • [50] Ekinci D, Karagoz L, Ekinci D, Senturk M, Supuran CT. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. Journal of enzyme inhibition and medicinal chemistry 2013, 28(2), 283-288.
  • [51] Gocer H, Topal F, Topal M, Küçük M, Teke D, Gülçin İ, Supuran CT. Acetylcholinesterase and carbonic anhydrase isoenzymes I and II inhibition profiles of taxifolin. Journal of enzyme inhibition and medicinal chemistry 2016, 31(3), 441-447.
  • [52] Kuzu M, Özkaya A, Şahin Z, Dağ Ü, Comakli V, Demirdağ R. In Vivo Effects of Naringenin and Lead on Rat Erythrocyte Carbonic Anhydrase Enzyme. Turk J Pharm Sci 2017, 14(1), 9-12.
  • [53] Kuzu M and Ciftci M. Purification and characterization of NADPH-cytochrome P450 reductase from Lake Van fish liver microsomes and investigation of some chemical and metals’ effects on the enzyme activity. Turkish journal of chemistry 2015, 39 (1), 149-158.
  • [54] Katzenmeyer JB, Eddy CV and Arriaga EA. Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin. Analytical Chemistry 2010, 82 (19), 8113–8120.
  • [55] Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature reviews cancer 2011, 11(2), 85–95.
  • [56] Lin R, Elf S, Shan C, Kang HB, Ji Q. Zhou L,...Xie J. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1–AMPK signalling. Nature cell biology 2015, 17(11), 1484.
  • [57] Yang X, Peng X and Huang J. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clinical and translational oncology 2018, 20 (9), 1145–1152.
  • [58] Mitchell I and Deshpande N. Drug effects on certain enzymes of carbohydrate metabolism in MCF-7 cells in culture. Clinical oncology 1984, 10 (3), 253–260.
  • [59] Bindoli A, Rigobello MP, Scutari G, Gabbiani C, Casini A, Messori L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coordination Chemistry Reviews 2009, 253(11-12), 1692-1707.
  • [60] Arnér ESJ and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. European journal of biochemistry 2000, 267 (20), 6102-6109.
  • [61] Berggren M, Gallegos A, Gasdaska JR, Gasdaska P, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer research 1996, 16(6B), 3459-3466.
  • [62] Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, Moos PJ. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 2006, 27(12), 2538-2549.
  • [63] Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. Journal of Biological Chemistry 2006, 281(19), 13005-13008.
  • [64] Korać B and Buzadžić B. Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. Journal of dermatological science 2001, 25 (1), 45–52.
There are 61 citations in total.

Details

Primary Language English
Journal Section Articles
Authors

Ahmet Gökhan Ağgül 0000-0003-0377-0388

Müslüm Kuzu 0000-0002-1375-7673

Fatih Mehmet Kandemir This is me 0000-0002-8490-2479

Sefa Küçükler 0000-0002-8222-5515

Cüneyt Çağlayan 0000-0001-5608-554X

Project Number ECZF.17.001
Publication Date September 29, 2020
Submission Date October 13, 2019
Published in Issue Year 2020 Volume: 10 Issue: 3

Cite

APA Ağgül, A. G., Kuzu, M., Kandemir, F. M., Küçükler, S., et al. (2020). Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin. Clinical and Experimental Health Sciences, 10(3), 228-234. https://doi.org/10.33808/clinexphealthsci.632320
AMA Ağgül AG, Kuzu M, Kandemir FM, Küçükler S, Çağlayan C. Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin. Clinical and Experimental Health Sciences. September 2020;10(3):228-234. doi:10.33808/clinexphealthsci.632320
Chicago Ağgül, Ahmet Gökhan, Müslüm Kuzu, Fatih Mehmet Kandemir, Sefa Küçükler, and Cüneyt Çağlayan. “Alterations in Enzyme Activity of Carbonic Anhydrase, 6-Phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin”. Clinical and Experimental Health Sciences 10, no. 3 (September 2020): 228-34. https://doi.org/10.33808/clinexphealthsci.632320.
EndNote Ağgül AG, Kuzu M, Kandemir FM, Küçükler S, Çağlayan C (September 1, 2020) Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin. Clinical and Experimental Health Sciences 10 3 228–234.
IEEE A. G. Ağgül, M. Kuzu, F. M. Kandemir, S. Küçükler, and C. Çağlayan, “Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin”, Clinical and Experimental Health Sciences, vol. 10, no. 3, pp. 228–234, 2020, doi: 10.33808/clinexphealthsci.632320.
ISNAD Ağgül, Ahmet Gökhan et al. “Alterations in Enzyme Activity of Carbonic Anhydrase, 6-Phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin”. Clinical and Experimental Health Sciences 10/3 (September 2020), 228-234. https://doi.org/10.33808/clinexphealthsci.632320.
JAMA Ağgül AG, Kuzu M, Kandemir FM, Küçükler S, Çağlayan C. Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin. Clinical and Experimental Health Sciences. 2020;10:228–234.
MLA Ağgül, Ahmet Gökhan et al. “Alterations in Enzyme Activity of Carbonic Anhydrase, 6-Phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin”. Clinical and Experimental Health Sciences, vol. 10, no. 3, 2020, pp. 228-34, doi:10.33808/clinexphealthsci.632320.
Vancouver Ağgül AG, Kuzu M, Kandemir FM, Küçükler S, Çağlayan C. Alterations in Enzyme Activity of Carbonic Anhydrase, 6-phosphogluconate Dehydrogenase and Thioredoxin Reductase in Rats Exposed to Doxorubicin and Morin. Clinical and Experimental Health Sciences. 2020;10(3):228-34.

14639   14640